Clinical trial NCT00492232: Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia
Official title: Randomized, Double Blind, Placebo-Controlled Study to Assess Whether the Administration of Ramelteon Could Facilitate the Discontinuation of Zolpidem (Ambien®) ≥10 mg Therapy in Subjects With Chronic Insomnia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Chronic Insomnia
Keywords: Chronic Insomnia
Sleep Initiation and Maintenance Disorder
Drug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2007-06-27
Enrollment: 135
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess whether ramelteon, once daily (QD), can facilitate the discontinuation of zolpidem in subjects with chronic insomnia.

Detailed description: Approximately 60 to 70 million adults in the United States alone are affected by insomnia. Daytime symptoms of insomnia include tiredness, lack of energy, difficulty concentrating, and irritability. Recent epidemiologic research focusing on the quality of life has identified significant insomnia-related morbidities that relate to work productivity, health care utilization, and risk of depression. Insomnia is associated with diminished work output, absenteeism, and greater rates of accidents.

Zolpidem is the most commonly prescribed hypnotic in the United States for patients suffering from insomnia.

The purpose of this study is to assess whether ramelteon therapy can facilitate the discontinuation of benzodiazepine therapy in long term users. Subject participation in this study is anticipated to be about 17 weeks.

Subjects were screened and enrolled in a 4-week placebo run-in period, may have been randomized to a 10-week double-blind treatment period, and may have completed with a 2-week open-label treatment period. In the double-blind treatment period, subjects were randomized to one of two treatments: either ramelteon 8 mg tablets taken orally once-daily with concomitant current zolpidem therapy or to placebo-matching tablets once daily with concomitant current zolpidem therapy. Subjects incrementally reduced zolpidem therapy by dose, frequency, or both for up to 10 weeks. Only those subjects who completed the double-blind treatment period and had achieved a 50% reduction in zolpidem therapy during the double-blind treatment period participated in the open-label treatment period in which 8 mg ramelteon was administered. Zolpidem consumed during the open-label treatment period was recorded.

Eligibility criteria: Inclusion Criteria

* Chronic insomnia and taking greater than or equal to 10 mg zolpidem at least 4 times per week.
* Has been prescribed zolpidem for difficulty in initiating sleep.
* Must report chronic use of zolpidem greater than or equal to10 mg therapy for a minimum of 3 months prior to entry into Period 1 of the study.
* Must have taken zolpidem greater than or equal to 10 mg therapy for at least 4 of 7 days each week of the 4 weeks immediately prior to entry into the double blind phase, Period 2.
* Expressed a willingness to discontinue zolpidem therapy.
* Habitual bedtime is between 9:00 PM and 1:00 AM based on sleep history.
* Negative test result for hepatitis B surface antigen and hepatitis C virus antibody.
* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion Criteria

* Known hypersensitivity to ramelteon, zolpidem, or melatonin.
* Participated in any other investigational study and/or taken any investigational drug within 30 days prior to the first dose of run-in study medication.
* Sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the first night of run-in study medication.
* History of fibromyalgia, history of seizures, sleep apnea, restless leg syndrome, periodic leg syndrome, chronic obstructive pulmonary disease, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.
* History of drug addiction or drug abuse within the past 12 months.
* History of alcohol abuse within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition revised and/or regularly consumes more than 2 alcoholic drinks per day.
* Current significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication, within 30 days prior to the first night of run-in study medication.
* Body mass index of less than 18 or greater than 34 (weight /height2).
* Any clinically important abnormal finding as documented by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.
* Positive hepatitis panel.
* Known history of human immunodeficiency virus.
* Any additional conditions(s) that in the investigator's opinion would affect:

  * sleep/wake function
  * prohibit the subject from completing the study
  * indicate that continuation in the study would not be in the best interests of the subject.
* Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication, including:

  * Melatonin
  * Anxiolytics
  * Antipsychotics
  * Over-the-counter and prescription sedatives
  * Hypnotics (excluding zolpidem)
  * Narcotic analgesics
  * Antidepressants
  * Beta-blockers (exception is that Atenolol is permissible)
  * Anticonvulsants
  * St. John's wort
  * Sedating H1 antihistamines
  * Kava-kava
  * Systemic steroids
  * Ginkgo-biloba
  * Respiratory stimulants
  * Over-the-counter and prescription diet aids
  * Sedating Decongestants

Primary outcomes:
measure: Percentage of Participants Who Discontinued Zolpidem Therapy
timeFrame: Week 10
Secondary outcomes:
measure: Change From Baseline in Weekly Zolpidem Dosage During Weeks 1-2
timeFrame: Baseline and Weeks 1-2
measure: Change From Baseline in Weekly Zolpidem Dosage During Weeks 3-4
timeFrame: Baseline and Weeks 3-4
measure: Change From Baseline in Weekly Zolpidem Dosage During Weeks 5-6
timeFrame: Baseline and Weeks 5-6
measure: Change From Baseline in Weekly Zolpidem Dosage During Weeks 7-8
timeFrame: Baseline and Weeks 7-8
measure: Change From Baseline in Weekly Zolpidem Dosage During Weeks 9-10
timeFrame: Baseline and Weeks 9-10
measure: Change From Baseline in Weekly Zolpidem Frequency During Weeks 1-2
timeFrame: Baseline and Weeks 1-2
measure: Change From Baseline in Weekly Zolpidem Frequency During Weeks 3-4
timeFrame: Weeks 3-4
measure: Change From Baseline in Weekly Zolpidem Frequency During Weeks 5-6
timeFrame: Weeks 5-6
measure: Change From Baseline in Weekly Zolpidem Frequency During Weeks 7-8
timeFrame: Baseline and Weeks 7-8
measure: Change From Baseline in Weekly Zolpidem Frequency During Weeks 9-10
timeFrame: Baseline and Weeks 9-10
measure: Participants Who Completely Discontinued Zolpidem at the End of Double-Blind Treatment Period, by Method of Discontinuation
timeFrame: Weeks 1-10
measure: Participants Who Achieved a 50% Reduction in Zolpidem Dosage at the End of the Double-Blind Treatment Period
timeFrame: Baseline and Week 10
measure: Participants Who Achieved a 50% Reduction in Zolpidem Dosage at Any Time During the Double-Blind Treatment Period
timeFrame: Baseline and Weeks 1-10
Other outcomes:
Locations:
city: Hot Springs
country: United States
state: Arkansas
city: Anaheim
country: United States
state: California
city: Fountain Valley
country: United States
state: California
city: La Mesa
country: United States
state: California
city: Los Angeles
country: United States
state: California
city: Redlands
country: United States
state: California
city: San Diego
country: United States
state: California
city: San Francisco
country: United States
state: California
city: Santa Monica
country: United States
state: California
city: Denver
country: United States
state: Colorado
city: Clearwater
country: United States
state: Florida
city: Hollywood
country: United States
state: Florida
city: Kissimmee
country: United States
state: Florida
city: Naples
country: United States
state: Florida
city: Pembroke Pines
country: United States
state: Florida
city: Winter Park
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Austell
country: United States
state: Georgia
city: Boise
country: United States
state: Idaho
city: Louisville
country: United States
state: Kentucky
city: Metairie
country: United States
state: Louisiana
city: Chevy Chase
country: United States
state: Maryland
city: St. Louis
country: United States
state: Missouri
city: Lincoln
country: United States
state: Nebraska
city: New York
country: United States
state: New York
city: West Seneca
country: United States
state: New York
city: Raleigh
country: United States
state: North Carolina
city: Wilmington
country: United States
state: North Carolina
city: Cincinnati
country: United States
state: Ohio
city: Toledo
country: United States
state: Ohio
city: Portland
country: United States
state: Oregon
city: Philadelphia
country: United States
state: Pennsylvania
city: Greer
country: United States
state: South Carolina
city: Fayetteville
country: United States
state: Tennessee
city: Austin
country: United States
state: Texas
city: Dallas
country: United States
state: Texas
city: Fort Worth
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: San Angelo
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Salt Lake City
country: United States
state: Utah
Study officials:
affiliation: Takeda Global Research & Development Center
name: Medical Director Clinical Science
role: STUDY_DIRECTOR
References: